Plant-Based proteins with better therapeutic profiles

Protalix Biotherapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Its lead product, currently under FDA review for approval, is a bio-better long acting enzyme replacement therapy for Fabry’s disease, partnered with Chiesi.

Investing partner / fund: